Solide Tumoren
Diverse: ACT Immatics IMA 202-101
Phase 1 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with recurrent and/or refractory solid Tumors.Mehr…
Diverse: EMR 100036-002
First in man study with MEN1112, a CD157 targeted monoclonal antibody, in relapsed or refractory Acute Myeloid LeukemiaMehr…
Diverse: Merck MK 4280-001
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors.Mehr…
Glioblastom: AMG 596
Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 in Subjects With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).Mehr…
Diverse: MSD MK4621-002
A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination with Pembrolizumab (MK-3475) in Participants with advanced/Metastatic or Recurrent Solid Tumors.Mehr…